Blue Note Therapeutics
San Francisco, US · Founded 2018 · Delaware corporation · 3 known investors
Find your way into Blue Note Therapeutics
Leverages cutting-edge digital technology and neuroscience for the treatment of serious medical conditions.
Also known as Blue Note Therapeutics, Inc.
Founders & leadership
Investors · 3
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$15.5M disclosed across 1 of 3 rounds · 2021
▶$15.5MraisedAug 2021 · 4 investors · Other Health CareRule 506(b)
- Andrew FirlikDirector
- Geoffrey EichExecutive Officer, Director
- John HarrisDirector
- Offering amount
- $50M
- Amount sold
- $15.5M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Blue Note Therapeutics, Inc. is a San Francisco-based prescription digital therapeutics (PDT) company focused on patients experiencing cancer-related distress. The company develops clinically validated software-based medical devices intended to address the psychosocial needs of oncology patients and to reduce comorbidities such as anxiety, depression, and fear of cancer recurrence. Its approach combines clinical and scientific expertise, neuroscience, and digital product development, with the goal of extending evidence-based, cancer-specific psychosocial treatments used at leading cancer centers to a broader patient population.
The company's lead asset, BNT001, received Breakthrough Device Designation from the U.S. Food and Drug Administration in June 2020 for the treatment of symptoms of anxiety and depression related to cancer in adult patients; as of the March 2021 announcement it was not cleared by the FDA for any indication. In 2020 the company launched COVID Cancer Care, a digital wellness program for adults with cancer coping with stress and anxiety related to the COVID-19 pandemic, made available under the FDA's enforcement policy for digital health devices for treating psychiatric disorders during the COVID-19 public health emergency announced in April 2020. Beyond its lead program, Blue Note has described a pipeline of additional prescription digital therapeutic assets.
Business model
Blue Note develops prescription digital therapeutics, a class of medical devices using FDA-approvable software that must demonstrate safety and efficacy in randomized clinical trials before FDA approval, positioning its products as prescribed treatments delivered alongside oncology care.
Traction
Received FDA Breakthrough Device Designation for BNT001 in June 2020, launched the COVID Cancer Care digital wellness program in 2020, and raised a total of $31 million in Series A financing across two closings in 2021 to scale the organization and fund near-term clinical trials.
Latest developments
In September 2021 the company added $5.2 million to its Series A round from Memorial Sloan Kettering Cancer Center and Alumni Ventures, bringing the round total to $31 million, with proceeds directed at developing evidence-based therapeutics for a growing number of cancer patients.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positions itself as a prescription digital therapeutics company singularly dedicated to cancer-related distress, addressing a gap in which fewer than half of patients experiencing cancer-related distress are referred to mental health specialists.
Technology
Software-based medical devices that digitize evidence-based, cancer-specific psychosocial therapies, drawing on neuroscience and clinical research. The lead product candidate, BNT001, targets symptoms of anxiety and depression related to cancer in adults and holds FDA Breakthrough Device Designation.
Go-to-market
The company works with cancer research centers and patient communities and holds licensing agreements with leading cancer centers and universities, including the University of Miami, Massachusetts General Hospital, and Memorial Sloan Kettering Cancer Center, to digitize evidence-based cancer-specific therapies. Memorial Sloan Kettering Cancer Center is also an investor and has institutional financial interests related to the company.
Adult cancer patients and survivors experiencing cancer-related distress, anxiety, or depression, reached through oncology care settings; the company cites roughly 18 million cancer patients and survivors in the United States, nearly half of whom experience psychosocial distress, anxiety, or depression.
Geography
Headquartered in San Francisco, California, with products and market focus directed at patients in the United States.
History
The company announced the closing of a $26.25 million Series A round in March 2021, led by JAZZ Venture Partners with participation from Summer VC, following the June 2020 FDA Breakthrough Device Designation for BNT001 and the 2020 launch of its COVID Cancer Care program. In September 2021 it extended the Series A by $5.2 million with Memorial Sloan Kettering Cancer Center and Alumni Ventures.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsMemorial Sloan Kettering Cancer Center and Alumni Ventures provided $5.2 million in additional Series A financing, joining lead investors JAZZ Venture Partners and Summer VC.
$5.2M source ↗
Series A financing led by JAZZ Venture Partners with Summer VC, to scale the organization, fund near-term clinical trials of its lead prescription digital therapeutic, and support pipeline development.
$26.3M source ↗
Blue Note holds licensing agreements with institutions including the University of Miami, Massachusetts General Hospital, and Memorial Sloan Kettering Cancer Center to digitize evidence-based, cancer-specific therapies.
The FDA granted Breakthrough Device Designation to BNT001 for treatment of symptoms of anxiety and depression related to cancer in adult patients. BNT001 was not cleared by the FDA for any indication as of March 2021.
Digital wellness program to help adults with cancer cope with stress and anxiety related to the COVID-19 pandemic, offered under the FDA's April 2020 enforcement policy for digital health devices treating psychiatric disorders during the public health emergency.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 2
primary sources listed
- Blue Note Therapeutics Raises $26.25 Million in Series A Financingprnewswire.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Blue Note Therapeutics do?
- San Francisco prescription digital therapeutics company developing software-based treatments for cancer-related distress.
- Who are Blue Note Therapeutics's investors?
- Blue Note Therapeutics's investors include JAZZ Venture Partners, Summer VC.
- How much funding has Blue Note Therapeutics raised?
- Blue Note Therapeutics has disclosed $15.5M raised across 1 of its 3 known rounds.
- Where is Blue Note Therapeutics headquartered?
- Blue Note Therapeutics is headquartered in San Francisco, US.